Navigation Links
TauRx Expands Alzheimer's Clinical Trials in the United States
Date:1/6/2014

ABERDEEN, Scotland, Jan. 6, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd, a clinical-stage biopharmaceutical company developing a novel treatment for Alzheimer's disease, has expanded its international clinical trials by adding new research centers across the U.S. The addition of 35 clinical research centers means that more patients suffering from mild or moderate Alzheimer's, and their caregivers, will have an opportunity to see if they qualify for participation in TauRx's Alzheimer's clinical trials. Professor Claude M. Wischik, MD, TauRx's Co-founder and Chairman, said, "TauRx's treatment, LMTX™, being evaluated in Phase 3 clinical trials for Alzheimer's, will represent a breakthrough in dementia treatment if, as we hope to demonstrate, it slows and even halts the progression of the disease, as our earlier studies have shown."

"This compound is potentially a disease-modifying approach to treating Alzheimer's, targeting the tangles of tau protein that develop in the brain which are clearly linked to the progression of dementia," said Professor Wischik. "We are pleased to expand the number of research centers conducting our clinical trial to permit more people across the U.S. to access our study." Importantly, added Wischik, "Only by participating in clinical studies such as ours, can we collectively – in partnership with those living with Alzheimer's – help advance the essential research that can result in the development of new medicines for this terminal medical condition."

The main purpose of TauRx's Phase 3 clinical research studies is to evaluate the effects of LMTX™, a second generation tau aggregation inhibitor, on slowing and/or halting the progression of Alzheimer's disease. There is currently no cure for Alzheimer's, nor are there any current treatments that halt the progression of memory loss.

The expansion of study centers in the U.S. means that eligible patients in areas such as Bennington, Vermont; Farmington Hills, Michigan; Waukesha, Wisconsin; and Creve Coeur, Missouri can also participate in the studies.

With 5.2 million Americans living with Alzheimer's, chances are you probably know someone who is affected by Alzheimer's. You may have friends or family members who are living with Alzheimer's, which is currently the 6th leading cause of death in the U.S. To learn more about TauRx, please visit www.taurx.com. Patients and caregivers who are interested in learning more about potentially participating in TauRx's Alzheimer's clinical trials can visit www.AlzheimersPressRelease.com or call 1-855-786-7259.

About TauRx Therapeutics
TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases. The company's tau aggregation inhibitor, LMTX™, is currently in global Phase 3 clinical trials for Alzheimer's and Frontotemporal Dementia (FTD). LMTX™ targets aggregates of abnormal fibers of tau protein that form inside nerve cells in the brain, giving rise to tau tangles. TauRx's primary research facilities are in Aberdeen, Scotland.

About  Alzheimer's Disease and Tau Tangles
Alzheimer's disease is one of the most important health challenges worldwide, and the most common cause of dementia. According to the Geneva-based World Health Organization and Alzheimer's Disease International, global dementia cases are expected to triple by 2050 to an estimated 135 million people.  One of the hallmark signs of Alzheimer's, tau tangles, are present in the same regions of the brain where neuronal degeneration and loss of neuronal cells eventually occur. These changes first appear 20-30 years before the disease becomes clinically evident.


'/>"/>
SOURCE TauRx Therapeutics Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
2. SMI Expands Eye Tracking Business with Office in San Francisco
3. PTS, Inc. Acquires A1CNow and Expands Product Portfolio
4. Smithers Quality Assessments Expands Certification Services to Include Pharmaceuticals Industry
5. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
6. GSW Launches Multi-Channel Detailing Platform and Expands Closed-Loop Marketing Suite
7. Life Science Company Calbiotech Expands Holdings with Moduline Systems
8. Giant Eagle Expands Specialty Pharmacy with Acquisition, Bringing Treatment Expertise to Customers with Hepatitis C and Organ Transplant Conditions
9. Hologic Expands its Board of Directors with Appointment of Two Independent Directors and Engages Chairman of Mt. Sinai Radiology Department as Scientific Advisor
10. Shanghai Ajinomoto Amino Acid Co., Ltd. Expands Amino Acid Production Capacity
11. Omnicell Expands its Unity Platform to Further Integrate Workflows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... June 23, 2016 Research and ... Procedure Volumes: Global Analysis (United States, China, Japan, Brazil, ... report to their offering. ... for healthcare business planners, provides surgical procedure volume data ... trends with an in-depth analysis of growth drivers and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
Breaking Medicine News(10 mins):